On the question of some correlation links of the metabolic syndrome and nonalcoholic fatial liver disease

The study of the correlation of metabolic syndrome and non-alcoholic fatty liver disease. Steatal changes in the liver, which can act as an initiating component of the metabolic syndrome. Communication NAFTLD with hyperlipidemia noted by many researchers.

Рубрика Медицина
Вид статья
Язык английский
Дата добавления 29.04.2019
Размер файла 15,6 K

Отправить свою хорошую работу в базу знаний просто. Используйте форму, расположенную ниже

Студенты, аспиранты, молодые ученые, использующие базу знаний в своей учебе и работе, будут вам очень благодарны.

Размещено на http://www.allbest.ru//

Размещено на http://www.allbest.ru//

On the question of some correlation links of the metabolic syndrome and nonalcoholic fatial liver disease

Mosina L.M.

К ВОПРОСУ О НЕКОТОРЫХ КОРРЕЛЯЦИОННЫХ ВЗАИМОСВЯЗЯХ МЕТАБОЛИЧЕСКОГО СИНДРОМА И НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ

Мосина Л.М.

Аннотация

Данный обзор литературы посвящен корреляционным взаимосвязям метаболического синдрома и неалкогольной жировой болезни печени (НЖБП). Сегодня мировая практика исследований требует всестороннего подхода к изучению заболеваний, что обусловлено мультифакторным подходом. Пожалуй, наиболее значимыми в формировании НЖБП являются: сахарный диабет 2 типа, инсулинорезистентность, ожирение, так как они в свою очередь выступают самыми значимыми компонентами метаболического синдрома. Но по-прежнему дискутабельным вопросом являются стеатозные изменения в печени, которые могут выступить в качестве инициирующе компонента метаболического синдрома.

Ключевые слова: метаболический синдром, неалкогольная жировая болезнь печени.

ON THE QUESTION OF SOME CORRELATION LINKS OF THE METABOLIC SYNDROME AND NONALCOHOLIC FATIAL LIVER DISEASE

Research article

Mosina L.M.1, Korobkov D.M.2, *, Stepanov N.Yu.3, Titojkina Yu.V.4, Kumanyaeva D.Yu.5, Rahmatullina M. A.6, Surgaeva E. I.7, Mokina E. A.8

Abstract

This review of the literature is devoted to the correlation relationships of metabolic syndrome and non-alcoholic fatty liver disease (NAFTLD). Today, the world practice of research requires a comprehensive approach to the study of diseases, due to the multifactorial approach. Perhaps the most significant in the formation of NBBP are: insulin resistance, type 2 diabetes, dyslipidemia, obesity, and they, in turn, are the most important components of the metabolic syndrome. But still a debatable issue are steatal changes in the liver, which can act as an initiating component of the metabolic syndrome.

Keywords: metabolic syndrome, non-alcoholic fatty liver disease.

There is a view that non-alcoholic fatty liver disease (NAFTLD) is a manifestation of the metabolic syndrome (MS) [1, P. 2062], [10, P. 664]. Interest in NAFTLD is due to the prevalence of this disease among the population. NAFTLD is one of the most extensive forms of liver disease in all countries. According to world statistics, the prevalence of NAFTLD is 20-30% [2, P. 390]. In the Russian Federation, the results of an open randomized prospective study observation of DIREG_L_01903 NAFTLD were found in 26,1% of patients, among whom liver cirrhosis was detected in 3%, steatosis - in 79,9%, steatohepatitis - in 17,1% [3, P. 335], [11, P. 303]. More often, NAFTLD is detected in patients with diabetes mellitus (up to 63%) and obesity (up to 93%). The risk of NAFTLD disease is equal in people of different ages and nationalities [2, Р. 393].

Many NAFTLD researchers see IT as an integral part of the MS. The frequency of occurrence of NAFTLD varies from 14 to 26%, in addition, 10% of patients show signs non-alcoholic steatohepatitis [4, P. 92], [6, P. 7238].

It used to be considered that NAFTLD is easy, but then it turned out that NAFTLD leads to cirrhosis in 4-30% of cases, and steatohepatitis leads to fibrosis, and then to liver necrosis.

Since 2003, following the results of the 1st World Congress on IR, held in the USA, it has been decided that NAFTLD, along with hypertension and type 2 DM, is part of МS [5, P. 18].

F. Angelico et al. In 2015, 308 patients with MS were examined, and NAFTLD was found in 95,5% of patients, with a positive correlation between steatosis and MS clinical manifestations [12, Р. 325].

Severe forms of steatosis are usually associated with the presence of 5 clinical and biochemical signs of MS according to ATP III criteria. The first research in this direction was conducted by Marchesini et al. (2016), 304 patients with NAFTLD were examined for signs of metabolic syndrome in 88% of cases [9, P. 475].

Japanese doctors examined 4401 people with a normostenic body constitution, in which NAFTLD was clinically confirmed only in 18%, after one year NAFTLD was detected in 10% of patients, which the authors associate with MS [8, P. 12].

NAFTLD is a manifestation of MS, and its pathogenesis is based on insulin resistance (IR), even in 2013, a study was conducted, according to the results of which M. Rashid and E. Roberts suggested that IR is the cause of fat accumulation in [6, Р. 7238]. Proponents of this theory claim that liver steatosis is the result of an increase in the accumulation of free fatty acids in the IR. The association of NAFTLD with MS manifestations, especially in the most severe stages of liver disease, confirms the reason for the role of IR [6, Р. 7239]. A number of authors believe that the additional deposition of fat in the liver reduces the sensitivity of hepatocytes to insulin, which leads to resistance to hepatic insulin. T. Wannan et al. (2016) NAFTLD and hepatic IR without peripheral IR were detected in an experiment in rats after 3 days of feeding with a high percentage of fat. Prevention of fatty liver leads to increased insulin sensitivity [9, Р. 475]. Similar results were also obtained by Boden et al. (2007) and L.Ryssy (2015). The degree of IR was proportional to the concentration of free fatty acids in the liver.

L. Ryyssy et al. (2015) observed that NAFTLD in patients with type 2 DM determined the amount of insulin needed to correct hyperglycemia.

Other authors share the opinion that the accumulation of free fatty acids can occur without the development of peripheral IR, but the hepatic IR develops.

Steatosis is a secondary condition to IR and dyslipidemia, which complicates its therapy. Interesting results were obtained in the study of David et al. (2016) in which 63% of patients with obesity and type 2 diabetes had NAFTLD. At the same time, the authors note that among these patients, the detected IR is significantly higher than among patients with type 2 diabetes without the development of NAFTLD. These data are consistent with the opinion оf M. Giloter (2015) [12, P. 325].

NAFTLD is closely associated with obesity. The survey S. Bellentani (2016), of 66 obese people revealed the presence of NAFTLD in 87,5%. The study Varceau P. et al. of 555 patients with obesity grade 3: 86% had steatosis, 24% - steatohepatitis, 75% - fibrosis, 2 % - liver cirrhosis. According to A. O. Bauerova et al. (2005) obesity is associated with the development of steatosis in 95% of cases and with the development of NAFTLD in 20-47%. In 75% of patients with NAFTLD the body mass index increased by 10-42% in comparison with the norm and Stepanov steatosis is directly proportional to the degree of obesity. According to other data, the prevalence of obesity in people with NAFTLD varies from 30 to 100%.

According to T. Gottoet al. (2014) NAFTLD is associated with abdominal obesity. The Central localization of fat is detected in patients with NAFTLD, not obese [7, P. 360]. This is explained by the fact that in the case of excess portal or intraperitoneal fat can increase the flow of free fatty acids through the portal vein to the liver with the development of steatosis.

On the contrary, there is an alternative view that the greater impact on the formation of the NAFTLD has an excess of extraperitoneal fat mass.

Steppala-Lindroos et al. (2016) in their study showed that fat accumulation in the liver develops independently of intra - or extraabdominal fat distribution. Several studies have generally not revealed the relationship between the development NAFTLD and abdominal obesity [4, P. 91].

The view that diabetes type 2 develops NAFTLD shared by many authors. A number of studies have revealed the development of NAFTLD in 75% of patients with type 2 diabetes. In turn, type 2 diabetes mellitus and increased blood glucose levels were noted in 34-75% of patients with NAFTLD. Other authors point to the high prevalence of carbohydrate metabolism disorders in patients with NAFTLD. H. Knkobler et al. (2009) a study of 48 cases of NAFTLD revealed type 2 DM in 44%. In a similar study conducted by Younossi Z. et al. (2014) type 2 DM is detected in 33% of patients, with the severity of NAFTLD was higher in patients with type 2 DM [10, P. 667], [11, P. 308].

There is now strong evidence that NAFTLD often precedes the development of DM 2. NAFTLD is simply «hepatic manifestation» MS is out of date. NAFTLD is an important factor in the onset of diabetes and an early sign of diabetes and other clinical manifestations of MS.

Communication NAFTLD with hyperlipidemia has been noted by many researchers. It is well known that NAFTLD with hypercholesterols is more common. Along with this, the majority of patients with NAFTLD revealed a decrease in blood cholesterol Low density lipoprotein. According to D. Nievelis et al. (2017), liver steatosis may affect the severity of dyslipidemia in type 2 DM.

There are some studies showing the relationship of NAFTLD with hypertension. For example, in the study of J. Dixon et al. (2014) with 105 patients with NAFTLD, high IR index and hypertension were independent risk indicators for the development of NAFTLD [10, P. 667]. The connection of NAFTLD with IHD also emphasizes the common mechanisms of development of the above diseases in MS, in addition, NAFTLD is often combined with gallbladder dyskinesia.

Thus, it follows from the literature review that, despite the abundance of works, there are many contradictions that require further research in this area.

metabolic syndrome liver fatty

References

Ahmed A. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes/ A. Ahmed, R.J. Wong, S.A. Harrison//Clin. Gastroenterology Hepatology. -2015. -Vol.13 (12). -P. 2062-2070.

Angulo P. Liver brosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease/ P. Angulo, D.E. Kleiner, S. Dam-Larsen//Gastroenterology. -2015. -Vol. 149(2). -P. 389-397.

Anstee Q.M. Progression of NAFTLD to diabetes mellitus, cardiovascular disease or cirrhosis/ Q.M. Anstee, G. Targher, C.P. Day // Nat Rev Gastroenterology Hepatology. -2016. -Vol. 10. -P. 330-344.

Doycheva I. Non-invasive screening of diabetics in primary care for NAFTLD and advanced brosis by MRI and MRE/ I. Doycheva, J. Cui, P. Nquyen// Aliment Pharmacol Ther. -2016. -№43(1). -P. 83-95.

Kumar M.S. Cardiovascular Autonomic Dysfunction in Patients of Nonalcoholic Fatty Liver Disease/ M.S. Kumar, A. Singh, A. K. Jaryal// International Journal of Hepatology «Hindawi». -2016. -№54 (12). -P.18.

Micolasevic I. Transient elastography (FibroScan) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Were du we stand/I. Micolasevic // World J. Gastroenterol. -2016. -№22(32). - P. 7236 - 7251.

Mullur R. Thyroid hormone regulation of metabolism/R. Mullur// Physiological reviews. -2014. -№94(2). -P.355- 382.

Samuel V.T. The pathogenesis of insulin resistance: Integrating signaling pathways and substrateux/ V.T. Samuel, G.I. Shulman// J. Clin Invest. -2016. -№126(1). -P. 12-22.

Sumida Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis/ Y. Sumida, Y. Nakajima// World J. Gastroenterol. -2014. -№20(2). -P.475.

Targher G. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes/ G. Targher, F. Valbusa, S. Bonapace, L. Bertolini// Nutr. Metab. Cardiovasc. -2017. -№24. -P. 663-669.

Targher G. Nonalcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes// G. Targher, A. Mantovani, I. Pichiri, R. Rigolon/ Clin. Sci. (Lond). -2017. -№125. -P. 301-309.

Xhyheri B. Heart Rate Variability Today. / B. Xhyheri, O. Manfrini, M. Mazzolini, C. Pizzi// Progress in Cardiovascular Diseases. -2015. -№55 (3). -P. 321-331.

Размещено на Allbest.ru


Подобные документы

  • Infectious hepatitis - a widespread acute contagious disease. Botkin’s Disease is a viral disease that destroys the liver and bile ducts. Anatomy of the liver. The value of the liver to the body. Causes and signs of the disease. Treatment and prevention.

    презентация [4,0 M], добавлен 24.04.2014

  • Anatomy of the liver. Botkin’s disease is a viral disease that destroys the liver and bile ducts. Causes and treatment of the disease. Vaccinations and personal hygiene are the main means of prevention. Signs and symptoms of the Botkin’s disease.

    презентация [3,5 M], добавлен 22.04.2013

  • Churg-Strauss syndrome, microscopic polyangiitis as one of the basic types of the small vessel vasculitis. Specific features of differential diagnosis of pulmonary-renal syndrome. Characteristics of the anti-neutrophil cytoplasmic autoantibodies.

    презентация [8,2 M], добавлен 18.10.2017

  • The pathological process Acute Respiratory Distress Syndrome (ARDS). Specific challenges in mechanical ventilation of patients with ARDS. Causes of ARDS, and differential diagnosis. Treatment strategies and evidence behind them. Most common causes ARDS.

    презентация [2,6 M], добавлен 21.05.2015

  • Definition, pathophysiology, aetiologies (structural lesions, herniation syndromes, metabolic disturbances) of coma. Physical examination and investigations. Differential diagnosis - the pseudocomas. Prognostic signs in coma from global cerebral ischemia.

    презентация [875,4 K], добавлен 24.03.2015

  • Сущность синдрома Шершевского-Тернера (Turner syndrome). Распространенность и причины, этиология и патогенез. Диагностические признаки. Частота встречаемости патологических признаков. Программа обследования при этом синдроме. Симптоматическое лечение.

    презентация [280,8 K], добавлен 03.04.2014

  • The characteristic features of the two forms of eating disorders: anorexia nervosa and bulimia. Description body dysmorphic disorder syndrome as a teenager painful experiences of his "physical disability." Methods of treatment and prevention of disease.

    курсовая работа [17,9 K], добавлен 31.03.2013

  • Ulcer - is a defect of gastric or duodenal mucosa which interfere over lamina muscularis mucosae, submucosa. Pathogenesis of the disease, its provocative factors. Classification and types of ulcers. Symptoms of gastric ulcer disease, complications.

    презентация [1,9 M], добавлен 16.04.2014

  • Agranulocytosis - pathologic condition, which is characterized by a greatly decreased number of circulating neutrophils. Epidemiology and pathophysiology of this disease. Hereditary disease due to genetic mutations. Signs and symptoms, treatment.

    презентация [1,8 M], добавлен 25.02.2014

  • The major pathogens and symptoms of cholera - an acute intestinal anthroponotic infection caused by bacteria of the species Vibrio cholerae. Methods of diagnosis and clinical features of disease. Traditional methods of treatment and prevention of disease.

    презентация [1,0 M], добавлен 22.09.2014

Работы в архивах красиво оформлены согласно требованиям ВУЗов и содержат рисунки, диаграммы, формулы и т.д.
PPT, PPTX и PDF-файлы представлены только в архивах.
Рекомендуем скачать работу.